IL143279A0 - Novel therapeutic application of low molecular weight heparin - Google Patents

Novel therapeutic application of low molecular weight heparin

Info

Publication number
IL143279A0
IL143279A0 IL14327999A IL14327999A IL143279A0 IL 143279 A0 IL143279 A0 IL 143279A0 IL 14327999 A IL14327999 A IL 14327999A IL 14327999 A IL14327999 A IL 14327999A IL 143279 A0 IL143279 A0 IL 143279A0
Authority
IL
Israel
Prior art keywords
molecular weight
low molecular
weight heparin
therapeutic application
novel therapeutic
Prior art date
Application number
IL14327999A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL143279A0 publication Critical patent/IL143279A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • External Artificial Organs (AREA)
IL14327999A 1998-12-17 1999-12-13 Novel therapeutic application of low molecular weight heparin IL143279A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9815919A FR2787329B1 (fr) 1998-12-17 1998-12-17 Nouvelle application therapeutique des heparines de bas poids moleculaire
PCT/FR1999/003109 WO2000035462A1 (fr) 1998-12-17 1999-12-13 Nouvelle application therapeutique des heparines de bas poids moleculaire

Publications (1)

Publication Number Publication Date
IL143279A0 true IL143279A0 (en) 2002-04-21

Family

ID=9534065

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14327999A IL143279A0 (en) 1998-12-17 1999-12-13 Novel therapeutic application of low molecular weight heparin
IL143279A IL143279A (en) 1998-12-17 2001-05-21 Use of low molecular weight heparin for the preparation of pharmaceutical preparations for the treatment of motoneuronic diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143279A IL143279A (en) 1998-12-17 2001-05-21 Use of low molecular weight heparin for the preparation of pharmaceutical preparations for the treatment of motoneuronic diseases

Country Status (15)

Country Link
US (4) US20020040013A1 (xx)
EP (1) EP1140119B1 (xx)
JP (1) JP2002532431A (xx)
AT (1) ATE273711T1 (xx)
AU (1) AU1569700A (xx)
CA (1) CA2354762C (xx)
DE (1) DE69919578T2 (xx)
DK (1) DK1140119T3 (xx)
ES (1) ES2222748T3 (xx)
FR (1) FR2787329B1 (xx)
IL (2) IL143279A0 (xx)
NO (1) NO20012849L (xx)
PT (1) PT1140119E (xx)
SI (1) SI1140119T1 (xx)
WO (1) WO2000035462A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
US7511026B2 (en) 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
US20070134260A1 (en) * 2003-03-28 2007-06-14 Georg Feger Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
FR3000746A1 (fr) 2013-01-04 2014-07-11 Centre Nat Rech Scient Peptide pour son utilisation dans le traitement des neuronopathies motrices
RU2639574C2 (ru) * 2016-05-23 2017-12-21 Алексей Георгиевич Александров Способ получения низкомолекулярного гепарина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
JPH04507234A (ja) * 1988-04-22 1992-12-17 ベイラー・カレッジ・オブ・メディスン 筋萎縮性側索硬化症の治療用組成物の製造方法
CA2071898A1 (en) * 1989-10-27 1991-04-28 Diane M. Snow Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
FR2763849B1 (fr) * 1997-05-28 2000-09-15 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof

Also Published As

Publication number Publication date
CA2354762C (fr) 2010-02-09
SI1140119T1 (en) 2004-10-31
FR2787329A1 (fr) 2000-06-23
DE69919578D1 (de) 2004-09-23
CA2354762A1 (fr) 2000-06-22
FR2787329B1 (fr) 2001-02-09
IL143279A (en) 2006-12-10
DE69919578T2 (de) 2005-07-14
EP1140119B1 (fr) 2004-08-18
US20030236222A1 (en) 2003-12-25
AU1569700A (en) 2000-07-03
JP2002532431A (ja) 2002-10-02
DK1140119T3 (da) 2004-12-20
NO20012849D0 (no) 2001-06-08
EP1140119A1 (fr) 2001-10-10
ES2222748T3 (es) 2005-02-01
PT1140119E (pt) 2004-11-30
US20060100175A1 (en) 2006-05-11
NO20012849L (no) 2001-06-08
US20020040013A1 (en) 2002-04-04
WO2000035462A1 (fr) 2000-06-22
US20040038938A1 (en) 2004-02-26
ATE273711T1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
EP0626174A3 (en) Method and composition for the prophylaxis and / or treatment of underactive organs.
FI972793A0 (fi) Nebivololin käyttö antiaterogeenisenä aineena
WO2000021513A3 (en) Methods for treating multiple sclerosis
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
FI974640A0 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
AU1278600A (en) Novel therapeutic application of nicergoline
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
DE69814993D1 (de) Quasi-azeotrope Mischungen auf Basis von 1,1,1,3,3,-Pentafluorobutan, Methylene Chloride und Methanol zur Behandlung von festen Oberflächen
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
FI103753B (fi) Menetelmä väkirehun käsittelemiseksi
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate

Legal Events

Date Code Title Description
KB20 Patent renewed for 20 years
FF Patent granted